CBD Research for Practitioners- Peer-reviewed Scientific Resources

Browse Medical Research Based on Condition

FOR ACNE
FOR ADD / ADHD
FOR ADDICTION
FOR ALS
FOR ALZHEIMERS
FOR ANOREXIA
FOR ANXIETY
FOR ATHEROSCLEROSIS
FOR ARTHRITIS
FOR ASTHMA
FOR AUTISM
FOR BIPOLAR AFFECTIVE DISORDER
FOR CANCER – GENERAL
FOR CANCER – LUNG

FOR CANCER – PROSTATE/COLON
FOR CANCER – BREAST
FOR CANCER – BRAIN
FOR CANCER – LEUKEMIA
FOR CANCER – SKIN
FOR CANCER – ENDOCRINE
FOR CANCER – BLADDER
FOR CANCER – PAIN RELIEF
FOR CROHNS & COLITIS
FOR DEPRESSION
FOR ENDOCRINE DISORDERS
FOR FIBROMYALGIA
FOR GLAUCOMA
FOR HEART DISEASE

FOR HUNTINGTONS DISEASE
FOR INFLAMMATION
FOR IRRITABLE BOWEL SYNDROME
FOR KIDNEY DISEASE
FOR LIVER DISEASE
FOR METABOLIC SYNDROME
FOR MIGRAINES
FOR MOOD DISORDERS
FOR MOTION SICKNESS
FOR MULTIPLE SCLEROSIS
FOR NAUSEA
FOR NEURODEGENERATION
FOR NEUROPATHIC PAIN
FOR OBESITY

FOR OCD
FOR PARKINSONS DISEASE
FOR PRION
FOR PTSD
FOR RHEUMATISM
FOR SCHIZOPHRENIA
FOR SICKLE CELL ANEMIA
FOR SKIN CONDITIONS
FOR SLEEP DISORDERS
FOR SPINAL CORD INJURY
FOR STRESS
FOR STROKE/TBI

FOR ACNE

	FOR ACNE	Cannabidiol as a Treatment for Acne?
	FOR ACNE	Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
	FOR ACNE	The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities
	FOR ACNE	Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling
	FOR ACNE	Endocannabinoid signaling and epidermal differentiation

FOR ADD / ADHD

	FOR ADD / ADHD	Searching for a Neurobiological Basis for Self-Medication Theory in ADHD Comorbid With Substance Use Disorders
	FOR ADD / ADHD	Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats
	FOR ADD / ADHD	Subtypes of Attention Deficit — Hyperactivity Disorder (ADHD) and cannabis use
	FOR ADD / ADHD	Childhood and current ADHD symptom dimensions are associated with more severe cannabis outcomes in college students
	FOR ADD / ADHD	Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report
	FOR ADD / ADHD	Fitness to drive in spite (because) of THC

FOR ADDICTION

	FOR ADDICTION	Cannabidiol reduces cigarette consumption in tobacco smokers
	FOR ADDICTION	Cannabidiol inhibits the reward-facilitating effect of morphine
	FOR ADDICTION	Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances
	FOR ADDICTION	Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats
	FOR ADDICTION	Impact of Cannabis Use during Stabilization on Methadone Maintenance Treatment
	FOR ADDICTION	Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010
	FOR ADDICTION	Dysregulation of cannabinoid CB1 receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents
	FOR ADDICTION	Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity
	FOR ADDICTION	Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder
	FOR ADDICTION	Cannabidiol for the treatment of cannabis withdrawal syndrome

FOR ALS

	FOR ALS	Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials
	FOR ALS	ALS: delayed disease progression in mice by treatment with a cannabinoid
	FOR ALS	The (Endo)Cannabinoid System in Multiple Sclerosis and ALS
	FOR ALS	Survey of cannabis use in patients with ALS

FOR ALZHEIMERS

	FOR ALZHEIMERS	The therapeutic potential of the endocannabinoid system for Alzheimer’s disease
	FOR ALZHEIMERS	Endocannabinoid signalling in Alzheimer’s disease
	FOR ALZHEIMERS	A molecular link between the active component of marijuana and Alzheimer’s disease pathology
	FOR ALZHEIMERS	Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells
	FOR ALZHEIMERS	The Potential Therapeutic Effects of THC on Alzheimer’s Disease
	FOR ALZHEIMERS	The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease
	FOR ALZHEIMERS	Cannabinoids for the treatment of dementia
	FOR ALZHEIMERS	Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression
	FOR ALZHEIMERS	Cannabidiol: A promising drug for neurodegenerative disorders?
	FOR ALZHEIMERS	Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition
	FOR ALZHEIMERS	The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses
	FOR ALZHEIMERS	The role of phytochemicals in the treatment and prevention of dementia
	FOR ALZHEIMERS	Cannabinoids for the treatment of dementia
	FOR ALZHEIMERS	Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement
	FOR ALZHEIMERS	Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
	FOR ALZHEIMERS	Can Marijuana Prevent Alzheimer’s?

FOR ANOREXIA

	FOR ANOREXIA	Leptin, ghrelin, and endocannabinoids: Potential therapeutic targets in anorexia nervosa
	FOR ANOREXIA	The role of the endocannabinoid system in eating disorders: Neurochemical and behavioural preclinical evidence
	FOR ANOREXIA	Cancer cachexia and cannabinoids
	FOR ANOREXIA	Brain Type 1 Cannabinoid Receptor Availability in Patients with Anorexia and Bulimia Nervosa

FOR ANXIETY

	FOR ANXIETY	Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug
	FOR ANXIETY	Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa
	FOR ANXIETY	Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients
	FOR ANXIETY	Neural basis of anxiolytic effects of cannabidiol (Hemp Extract) in generalized social anxiety disorder
	FOR ANXIETY	Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation
	FOR ANXIETY	Effects of cannabidiol (Hemp Extract) on regional cerebral blood flow
	FOR ANXIETY	The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors
	FOR ANXIETY	The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
	FOR ANXIETY	Plant-based medicines for anxiety disorders, part 2: A review of clinical studies with supporting preclinical evidence

FOR ATHEROSCLEROSIS

	FOR ATHEROSCLEROSIS	The role of the endocannabinoid system in atherosclerosis
	FOR ATHEROSCLEROSIS	Cannabinoid receptors in atherosclerosis
	FOR ATHEROSCLEROSIS	The potential use of cannabidiol in the therapy of metabolic syndrome
	FOR ATHEROSCLEROSIS	Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice

FOR ARTHRITIS

	FOR ARTHRITIS	Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis
	FOR ARTHRITIS	The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
	FOR ARTHRITIS	The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55
	FOR ARTHRITIS	Arthritis and cannabinoids

FOR ASTHMA

	FOR ASTHMA	The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke
	FOR ASTHMA	Allergen challenge increases anandamide in bronchoalveolar fluid of patients with allergic asthma
	FOR ASTHMA	Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs
	FOR ASTHMA	Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways
	FOR ASTHMA	Bronchodilator effect of delta1-tetrahydrocannabinol

FOR AUTISM

	FOR AUTISM	Mutations found in individuals with autism interfere with endocannabinoid signaling in the brain
	FOR AUTISM	Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders
	FOR AUTISM	A novel approach to the symptomatic treatment of autism
	FOR AUTISM	Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders
	FOR AUTISM	Targeting the endocannabinoid system in the treatment of fragile X syndrome

FOR BIPOLAR AFFECTIVE DISORDER

	FOR BIPOLAR AFFECTIVE DISORDER	Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential
	FOR BIPOLAR AFFECTIVE DISORDER	Cannabidiol was ineffective for manic episode of bipolar affective disorder
	FOR BIPOLAR AFFECTIVE DISORDER	Effects of Co-occurring Cannabis Use Disorders on the Course of Bipolar Disorder After a First Hospitalization for Mania
	FOR BIPOLAR AFFECTIVE DISORDER	Does Cannabis Use Affect Treatment Outcome in Bipolar Disorder?: A Longitudinal Analysis
	FOR BIPOLAR AFFECTIVE DISORDER	The Use of Cannabis as a Mood Stabilizer in Bipolar Disorder: Anecdotal Evidence and the Need for Clinical Research

FOR CANCER - GENERAL

	FOR CANCER – GENERAL	Cannabidiol as potential anticancer drug
	FOR CANCER – GENERAL	Cannabidiol inhibits angiogenesis by multiple mechanisms
	FOR CANCER – GENERAL	The inhibitory effects of cannabidiol on systemic malignant tumors
	FOR CANCER – GENERAL	Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1
	FOR CANCER – GENERAL	Marijuana fights cancer and helps manage side effects

FOR CANCER - LUNG

	FOR CANCER – LUNG	Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1C
	FOR CANCER – LUNG	COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells
	FOR CANCER – LUNG	Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells
	FOR CANCER – LUNG	Media ignored expert’s shocking findings that marijuana helps prevent lung cancer

FOR CANCER - PROSTATE/COLON

	FOR CANCER – PROSTATE/COLON	Towards the use of non-psychoactive cannabinoids for prostate cancer
	FOR CANCER – PROSTATE/COLON	In Vitro Anticancer Activity of Plant-Derived Cannabidiol on Prostate Cancer Cell Lines
	FOR CANCER – PROSTATE/COLON	Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent
	FOR CANCER – PROSTATE/COLON	Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer
	FOR CANCER – PROSTATE/COLON	Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol

FOR CANCER - BREAST

	FOR CANCER – BREAST	Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma
	FOR CANCER – BREAST	Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy
	FOR CANCER – BREAST	Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis
	FOR CANCER – BREAST	Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
	FOR CANCER – BREAST	Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration

FOR CANCER - BRAIN

	FOR CANCER – BRAIN	Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival
	FOR CANCER – BRAIN	Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines(PubMed)
	FOR CANCER – BRAIN	Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas
	FOR CANCER – BRAIN	Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism
	FOR CANCER – BRAIN	Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target
	FOR CANCER – BRAIN	Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents
	FOR CANCER – BRAIN	Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect
	FOR CANCER – BRAIN	Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme

FOR CANCER - LEUKEMIA

	FOR CANCER – LEUKEMIA	Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression
	FOR CANCER – LEUKEMIA	Cannabidiol-Induced Apoptosis in Human Leukemia Cells
	FOR CANCER – LEUKEMIA	Cannabidiol Reduces Leukemic Cell Size – But Is It Important?
	FOR CANCER – LEUKEMIA	Targeting cannabinoid receptors to treat leukemia

FOR CANCER - SKIN

	FOR CANCER – SKIN	Anticancer activity of anandamide in human cutaneous melanoma cells
	FOR CANCER – SKIN	Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpes virus-infected endothelium (PubMed)
	FOR CANCER – SKIN	Cannabinoid receptors as novel targets for the treatment of melanoma
	FOR CANCER – SKIN	The Cannabinoid Receptors Are Required for Ultraviolet-Induced Inflammation and Skin Cancer Development

FOR CANCER - ENDOCRINE

	FOR CANCER – ENDOCRINE	Endocannabinoids in endocrine and related tumours
	FOR CANCER – ENDOCRINE	A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells
	FOR CANCER – ENDOCRINE	Cannabinoids in pancreatic cancer: Correlation with survival and pain
	FOR CANCER – ENDOCRINE	Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma

FOR CANCER - BLADDER

	FOR CANCER – BLADDER	TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer
	FOR CANCER – BLADDER	Association Between Cannabis Use and the Risk of Bladder Cancer
	FOR CANCER – BLADDER	Inhibitory Effect of Standardized Cannabis sativaExtract and Its Ingredient Cannabidiol on Rat and Human Bladder Contractility
	FOR CANCER – BLADDER	Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism

FOR CANCER - PAIN RELIEF

	FOR CANCER – PAIN RELIEF	Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:hemp extract and THC extract in patients with intractable cancer-related pain
	FOR CANCER – PAIN RELIEF	Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial
	FOR CANCER – PAIN RELIEF	Marijuana extract helps prevent chemo pain
	FOR CANCER – PAIN RELIEF	An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/Hemp Extract Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics

FOR CROHNS & COLITIS

	FOR CROHNS & COLITIS	Cannabidiol in inflammatory bowel diseases: a brief overview
	FOR CROHNS & COLITIS	Cannabis finds its way into treatment of Crohn’s disease
	FOR CROHNS & COLITIS	Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis
	FOR CROHNS & COLITIS	Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
	FOR CROHNS & COLITIS	The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
	FOR CROHNS & COLITIS	Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice
	FOR CROHNS & COLITIS	Cannabinoids and the gut: New developments and emerging concepts
	FOR CROHNS & COLITIS	Endocannabinoids and the gastrointestinal tract
	FOR CROHNS & COLITIS	Cannabinoids and gastrointestinal motility: Animal and human studies
	FOR CROHNS & COLITIS	Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis

FOR DEPRESSION

	FOR DEPRESSION	Endocannabinoid system dysfunction in mood and related disorders
	FOR DEPRESSION	Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa
	FOR DEPRESSION	The endocannabinoid system and the treatment of mood and anxiety disorders
	FOR DEPRESSION	Endocannabinoid signaling in the etiology and treatment of major depressive illness
	FOR DEPRESSION	Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors
	FOR DEPRESSION	Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants
	FOR DEPRESSION	Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa
	FOR DEPRESSION	Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress
	FOR DEPRESSION	Serum contents of endocannabinoids are correlated with blood pressure in depressed women
	FOR DEPRESSION	The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants
	FOR DEPRESSION	Antidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures

FOR ENDOCRINE DISORDERS

	FOR ENDOCRINE DISORDERS	Endocannabinoid system participates in neuroendocrine control of homeostasis
	FOR ENDOCRINE DISORDERS	The emerging role of the endocannabinoid system in endocrine regulation and energy balance
	FOR ENDOCRINE DISORDERS	Endocannabinoids in endocrine and related tumours
	FOR ENDOCRINE DISORDERS	Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas
	FOR ENDOCRINE DISORDERS	The role of the endocannabinoid system in the neuroendocrine regulation of energy balance
	FOR ENDOCRINE DISORDERS	Hemp Extract for children with Dravet’s and intractable seizures
	FOR ENDOCRINE DISORDERS	Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy
	FOR ENDOCRINE DISORDERS	Medicinal marijuana stops seizures, brings hope to a little girl
	FOR ENDOCRINE DISORDERS	Cannabinoids for epilepsy
	FOR ENDOCRINE DISORDERS	Cannabis, cannabidiol, and epilepsy – From receptors to clinical response
	FOR ENDOCRINE DISORDERS	The non-psychotropic plant cannabinoids, cannabidivarin and cannabidiol, activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability
	FOR ENDOCRINE DISORDERS	Chronic administration of cannabidiol to healthy volunteers and epileptic patients
	FOR ENDOCRINE DISORDERS	Endocannabinoid system protects against cryptogenic seizures
	FOR ENDOCRINE DISORDERS	Seizing an opportunity for the endocannabinoid system
	FOR ENDOCRINE DISORDERS	Cannabidiol: promise and pitfalls
	FOR ENDOCRINE DISORDERS	Cannabidivarin suppressespentylenetetrazole (PTZ)-inducedincreases in epilepsy-related gene expression
	FOR ENDOCRINE DISORDERS	Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
	FOR ENDOCRINE DISORDERS	Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo
	FOR ENDOCRINE DISORDERS	Hypnotic and antiepileptic effects of cannabidiol
	FOR ENDOCRINE DISORDERS	The cannabinoids as potential antiepileptics
	FOR ENDOCRINE DISORDERS	Cannabidiol–antiepileptic drug comparisons and interactions in experimentally induced seizures in rats

FOR FIBROMYALGIA

	FOR FIBROMYALGIA	Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
	FOR FIBROMYALGIA	Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life
	FOR FIBROMYALGIA	Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia
	FOR FIBROMYALGIA	Cannabinoids for fibromyalgia
	FOR FIBROMYALGIA	Medical Cannabis for the Treatment of Fibromyalgia

FOR GLAUCOMA

	FOR GLAUCOMA	Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite
	FOR GLAUCOMA	Cannabinoids and glaucoma
	FOR GLAUCOMA	The treatment of glaucoma using a non-psychoactive preparation of Cannabis sativa
	FOR GLAUCOMA	Cannabinoids for treatment of glaucoma

FOR HEART DISEASE

	FOR HEART DISEASE	Is the cardiovascular system a therapeutic target for cannabidiol?
	FOR HEART DISEASE	Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion
	FOR HEART DISEASE	Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy
	FOR HEART DISEASE	The Effect of Cannabidiol on Ischemia/Reperfusion-Induced Ventricular Arrhythmias: The Role of Adenosine A1 Receptors
	FOR HEART DISEASE	Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury
	FOR HEART DISEASE	Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension
	FOR HEART DISEASE	Oleamide: A fatty acid amide signaling molecule in the cardiovascular system?

FOR HUNTINGTONS DISEASE

	FOR HUNTINGTONS DISEASE	Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease
	FOR HUNTINGTONS DISEASE	Cannabinoids: Novel medicines for the treatment of Huntington’s disease
	FOR HUNTINGTONS DISEASE	Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB(1) and CB(2) receptors
	FOR HUNTINGTONS DISEASE	Controlled clinical trial of cannabidiol in Huntington’s disease
	FOR HUNTINGTONS DISEASE	Prospects for cannabinoid therapies in basal ganglia disorders
	FOR HUNTINGTONS DISEASE	Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice

FOR INFLAMMATION

	FOR INFLAMMATION	Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
	FOR INFLAMMATION	The endocannabinoid system: an emerging key player in inflammation
	FOR INFLAMMATION	Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice
	FOR INFLAMMATION	Cannabinoids, endocannabinoids, and related analogs in inflammation
	FOR INFLAMMATION	Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor
	FOR INFLAMMATION	Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
	FOR INFLAMMATION	Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis
	FOR INFLAMMATION	Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation
	FOR INFLAMMATION	Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement
	FOR INFLAMMATION	Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption
	FOR INFLAMMATION	Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
	FOR INFLAMMATION	Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death

FOR IRRITABLE BOWEL SYNDROME

	FOR IRRITABLE BOWEL SYNDROME	Cannabidiol in inflammatory bowel diseases: A brief overview
	FOR IRRITABLE BOWEL SYNDROME	Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis
	FOR IRRITABLE BOWEL SYNDROME	Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
	FOR IRRITABLE BOWEL SYNDROME	Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
	FOR IRRITABLE BOWEL SYNDROME	Therapeutic potential of cannabinoid-based drugs
	FOR IRRITABLE BOWEL SYNDROME	Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology)
	FOR IRRITABLE BOWEL SYNDROME	Cannabinoids and the gut: New developments and emerging concepts
	FOR IRRITABLE BOWEL SYNDROME	Endocannabinoids and the gastrointestinal tract
	FOR IRRITABLE BOWEL SYNDROME	Cannabinoids and gastrointestinal motility: Animal and human studies

FOR KIDNEY DISEASE

	FOR KIDNEY DISEASE	Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death
	FOR KIDNEY DISEASE	Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay
	FOR KIDNEY DISEASE	Is There a Legitimate Role for the Therapeutic Use of Cannabinoids for Symptom Management in Chronic Kidney Disease?
	FOR KIDNEY DISEASE	The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases

FOR LIVER DISEASE

	FOR LIVER DISEASE	The endocannabinoid system and liver diseases
	FOR LIVER DISEASE	Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death
	FOR LIVER DISEASE	Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis
	FOR LIVER DISEASE	Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats
	FOR LIVER DISEASE	Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol
	FOR LIVER DISEASE	Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice
	FOR LIVER DISEASE	Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation

FOR METABOLIC SYNDROME

	FOR METABOLIC SYNDROME	The impact of marijuana use on glucose, insulin, and insulin resistance among US adults
	FOR METABOLIC SYNDROME	The potential use of cannabidiol in the therapy of metabolic syndrome
	FOR METABOLIC SYNDROME	Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes
	FOR METABOLIC SYNDROME	Metabolic syndrome in people with a psychotic illness: is cannabis protective?
	FOR METABOLIC SYNDROME	Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome

FOR MIGRAINES

	FOR MIGRAINES	Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
	FOR MIGRAINES	Effects of anandamide in migraine: data from an animal model
	FOR MIGRAINES	Cannabinoids and hallucinogens for headache
	FOR MIGRAINES	The endocannabinoid system and migraine
	FOR MIGRAINES	Variations in the cannabinoid receptor 1 gene predispose to migraine

FOR MOOD DISORDERS

	FOR MOOD DISORDERS	Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
	FOR MOOD DISORDERS	The endocannabinoid system and the treatment of mood and anxiety disorders
	FOR MOOD DISORDERS	The endocannabinoid system and psychiatric disorders
	FOR MOOD DISORDERS	The endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives
	FOR MOOD DISORDERS	Endocannabinoid system dysfunction in mood and related disorders
	FOR MOOD DISORDERS	Effects of cannabidiol (hemp extract) on regional cerebral blood flow

FOR MOTION SICKNESS

	FOR MOTION SICKNESS	Motion sickness, stress and the endocannabinoid system
	FOR MOTION SICKNESS	Dexamethasone alleviates motion sickness in rats in part by enhancing the endocannabinoid system
	FOR MOTION SICKNESS	The Effects of Cannabidiol and Tetrahydrocannabinol on Motion‐Induced Emesis

FOR MULTIPLE SCLEROSIS

	FOR MULTIPLE SCLEROSIS	Sativex for the management of multiple sclerosis symptoms
	FOR MULTIPLE SCLEROSIS	THC and Hemp Extract oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
	FOR MULTIPLE SCLEROSIS	Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity
	FOR MULTIPLE SCLEROSIS	Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
	FOR MULTIPLE SCLEROSIS	Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial
	FOR MULTIPLE SCLEROSIS	Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis
	FOR MULTIPLE SCLEROSIS	Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis
	FOR MULTIPLE SCLEROSIS	A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
	FOR MULTIPLE SCLEROSIS	Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain(
	FOR MULTIPLE SCLEROSIS	Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain

FOR NAUSEA

	FOR NAUSEA	Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus
	FOR NAUSEA	Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation
	FOR NAUSEA	Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol in rats and shrews
	FOR NAUSEA	Regulation of nausea and vomiting by cannabinoids
	FOR NAUSEA	Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats
	FOR NAUSEA	Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting

FOR NEURODEGENERATION

	FOR NEURODEGENERATION	Cannabidiol: A promising drug for neurodegenerative disorders?
	FOR NEURODEGENERATION	Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?
	FOR NEURODEGENERATION	Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder
	FOR NEURODEGENERATION	Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders
	FOR NEURODEGENERATION	Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection

FOR NEUROPATHIC PAIN

	FOR NEUROPATHIC PAIN	Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
	FOR NEUROPATHIC PAIN	Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
	FOR NEUROPATHIC PAIN	Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine
	FOR NEUROPATHIC PAIN	Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial
	FOR NEUROPATHIC PAIN	Cannabinoids for neuropathic pain
	FOR NEUROPATHIC PAIN	Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue
	FOR NEUROPATHIC PAIN	Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
	FOR NEUROPATHIC PAIN	The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
	FOR NEUROPATHIC PAIN	Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
	FOR NEUROPATHIC PAIN	Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy
	FOR NEUROPATHIC PAIN	Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: Mechanisms involved
	FOR NEUROPATHIC PAIN	Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action
	FOR NEUROPATHIC PAIN	Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
	FOR NEUROPATHIC PAIN	Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes
	FOR NEUROPATHIC PAIN	Cannabinoids in the management of difficult to treat pain
	FOR NEUROPATHIC PAIN	Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:Hemp extract and THC extract in patients with intractable cancer-related pain
	FOR NEUROPATHIC PAIN	Marijuana extract helps prevent chemo pain
	FOR NEUROPATHIC PAIN	Pot users less likely to take painkillers

FOR OBESITY

	FOR OBESITY	The impact of marijuana use on glucose, insulin, and insulin resistance among US adults
	FOR OBESITY	Cannabinol and cannabidiol exert opposing effects on rat feeding patterns
	FOR OBESITY	Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss?
	FOR OBESITY	The endocannabinoid system in obesity and type 2 diabetes
	FOR OBESITY	Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk
	FOR OBESITY	Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes

FOR OCD

	FOR OCD	Plasma and brain pharmacokinetic profile of cannabidiol, cannabidivarine , Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and Hemp Extract action on obsessive-compulsive behaviour (PubMed)
	FOR OCD	Plasma and brain pharmacokinetic profile of cannabidiol , cannabidivarine , Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and hemp extract action on obsessive–compulsive behaviour
	FOR OCD	Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice

FOR PARKINSONS DISEASE

	FOR PARKINSONS DISEASE	Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
	FOR PARKINSONS DISEASE	Prospects for cannabinoid therapies in basal ganglia disorders
	FOR PARKINSONS DISEASE	Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: Importance of antioxidant and cannabinoid receptor-independent properties
	FOR PARKINSONS DISEASE	Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease
	FOR PARKINSONS DISEASE	Cannabidiol for the treatment of psychosis in Parkinson’s disease
	FOR PARKINSONS DISEASE	Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease
	FOR PARKINSONS DISEASE	Therapeutic potential of cannabinoids in CNS disease

FOR PRION

	FOR PRION	Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity
	FOR PRION	Cannabidiol: A prion therapy for mice?
	FOR PRION	Alteration of the endocannabinoid system in mouse brain during prion disease

FOR PTSD

	FOR PTSD	The endocannabinoid system provides an avenue for evidence-based treatment development for PTSD
	FOR PTSD	Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks
	FOR PTSD	Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear
	FOR PTSD	Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors
	FOR PTSD	Stress switches cannabinoid type-1 (CB1) receptor-dependent plasticity from LTD to LTP in the bed nucleus of the stria terminalis
	FOR PTSD	Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence
	FOR PTSD	Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment
	FOR PTSD	The endocannabinoid system and extinction learning
	FOR PTSD	A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers
	FOR PTSD	Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit
	FOR PTSD	Non-antidepressant long-term treatment in post-traumatic stress disorder
	FOR PTSD	The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system
	FOR PTSD	Modulation of Fear Memory by Dietary Polyunsaturated Fatty Acids via Cannabinoid Receptors

FOR RHEUMATISM

	FOR RHEUMATISM	Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
	FOR RHEUMATISM	Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases
	FOR RHEUMATISM	Clinical Implications for Cannabinoid Use in the Rheumatic Diseases
	FOR RHEUMATISM	Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases

FOR SCHIZOPHRENIA

	FOR SCHIZOPHRENIA	Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
	FOR SCHIZOPHRENIA	Cannabidiol as a potential treatment for psychosis
	FOR SCHIZOPHRENIA	Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
	FOR SCHIZOPHRENIA	Medical use of cannabis. Cannabidiol: A new light for schizophrenia?
	FOR SCHIZOPHRENIA	A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation
	FOR SCHIZOPHRENIA	Peripheral endocannabinoid system dysregulation in first-episode psychosis
	FOR SCHIZOPHRENIA	Cannabinoids and schizophrenia: Therapeutic prospects
	FOR SCHIZOPHRENIA	Antipsychotic-like effects of cannabidiol and rimonabant: Systematic review of animal and human studies
	FOR SCHIZOPHRENIA	Cannabidiol monotherapy for treatment-resistant schizophrenia
	FOR SCHIZOPHRENIA	Cannabis with high cannabidiol content is associated with fewer psychotic experiences
	FOR SCHIZOPHRENIA	Marijuana compound treats schizophrenia with few side effects: Clinical trial
	FOR SCHIZOPHRENIA	Clearing the smoke: what do we know about adolescent cannabis use and schizophrenia?

FOR SICKLE CELL ANEMIA

	FOR SICKLE CELL ANEMIA	Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: Modulation by cannabinoids
	FOR SICKLE CELL ANEMIA	Cannabis use in sickle cell disease: A questionnaire study
	FOR SICKLE CELL ANEMIA	Cannabinoid Receptor-Specific Mechanisms To Alleviate Pain In Sickle Cell Anemia Via Inhibition Of Mast Cell Activation And Neurogenic Inflammation

FOR SKIN CONDITIONS

	FOR SKIN CONDITIONS	Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis
	FOR SKIN CONDITIONS	Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
	FOR SKIN CONDITIONS	The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities
	FOR SKIN CONDITIONS	Epigenetic control of skin differentiation genes by phytocannabinoids
	FOR SKIN CONDITIONS	Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1
	FOR SKIN CONDITIONS	Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation
	FOR SKIN CONDITIONS	Attenuation of allergic contact dermatitis through the endocannabinoid system
	FOR SKIN CONDITIONS	Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus

FOR SLEEP DISORDERS

	FOR SLEEP DISORDERS	The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent
	FOR SLEEP DISORDERS	Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine
	FOR SLEEP DISORDERS	Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats
	FOR SLEEP DISORDERS	Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults
	FOR SLEEP DISORDERS	Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats
	FOR SLEEP DISORDERS	Endocannabinoid modulation of cortical up-states and NREM sleep
	FOR SLEEP DISORDERS	Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat

FOR SPINAL CORD INJURY

	FOR SPINAL CORD INJURY	Cannabidiol-treated rats exhibited higher motor score after cryogenic spinal cord injury
	FOR SPINAL CORD INJURY	Cannabis effect on spasticity in spinal cord injury
	FOR SPINAL CORD INJURY	An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease
	FOR SPINAL CORD INJURY	Modulation of Inflammatory Responses by a Cannabinoid-2–Selective Agonist after Spinal Cord Injury

FOR STRESS

	FOR STRESS	Endogenous cannabinoid signaling is essential for stress adaptation
	FOR STRESS	Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders
	FOR STRESS	Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output
	FOR STRESS	Neuromodulators, stress and plasticity: a role for endocannabinoid signalling
	FOR STRESS	Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress
	FOR STRESS	Endocannabinoids and stress
	FOR STRESS	Stress regulates endocannabinoid-CB1 receptor signaling
	FOR STRESS	Chronic Stress Impairs α1-Adrenoceptor-Induced Endocannabinoid-Dependent Synaptic Plasticity in the Dorsal Raphe Nucleus
	FOR STRESS	Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance
	FOR STRESS	Cannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression
	FOR STRESS	Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory
	FOR STRESS	The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
	FOR STRESS	Low-frequency stimulation evokes serotonin release in the nucleus accumbens and induces long-term depression via production of endocannabinoid

FOR STROKE/TBI

	FOR STROKE/TBI	Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury
	FOR STROKE/TBI	Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism
	FOR STROKE/TBI	Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism (
	FOR STROKE/TBI	Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function
	FOR STROKE/TBI	Protective Effects of Cannabidiol Against Hippocampal Cell Death and Cognitive Impairment Induced by Bilateral Common Carotid Artery Occlusion in Mice
	FOR STROKE/TBI	Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance

Browse Medical Research Based on Condition

FOR ACNE

FOR ADD / ADHD

FOR ADDICTION

FOR ALS

FOR ALZHEIMERS

FOR ANOREXIA

FOR ANXIETY

FOR ATHEROSCLEROSIS

FOR ARTHRITIS

FOR ASTHMA

FOR AUTISM

FOR BIPOLAR AFFECTIVE DISORDER

FOR CANCER - GENERAL

FOR CANCER - LUNG

FOR CANCER - PROSTATE/COLON

FOR CANCER - BREAST

FOR CANCER - BRAIN

FOR CANCER - LEUKEMIA

FOR CANCER - SKIN

FOR CANCER - ENDOCRINE

FOR CANCER - BLADDER

FOR CANCER - PAIN RELIEF

FOR CROHNS & COLITIS

FOR DEPRESSION

FOR ENDOCRINE DISORDERS

FOR FIBROMYALGIA

FOR GLAUCOMA

FOR HEART DISEASE

FOR HUNTINGTONS DISEASE

FOR INFLAMMATION

FOR IRRITABLE BOWEL SYNDROME

FOR KIDNEY DISEASE

FOR LIVER DISEASE

FOR METABOLIC SYNDROME

FOR MIGRAINES

FOR MOOD DISORDERS

FOR MOTION SICKNESS

FOR MULTIPLE SCLEROSIS

FOR NAUSEA

FOR NEURODEGENERATION

FOR NEUROPATHIC PAIN

FOR OBESITY

FOR OCD

FOR PARKINSONS DISEASE

FOR PRION

FOR PTSD

FOR RHEUMATISM

FOR SCHIZOPHRENIA

FOR SICKLE CELL ANEMIA

FOR SKIN CONDITIONS

FOR SLEEP DISORDERS

FOR SPINAL CORD INJURY

FOR STRESS

FOR STROKE/TBI

Shop Products

Resources

Learning Center

For Practitioners

Support

Connect WITH US